Abstract

Insulin lispro (Humalog - Lilly) is a genetically engineered human insulin analogue which the manufacturer claims to allow patients "the convenience of injecting immediately before they eat". It is licensed for the treatment of patients who require insulin therapy for maintenance of normal glucose homeostasis and for the initial stabilisation of diabetes mellitus. Here we review insulin lispro and assess its place in the treatment of patients with diabetes.